	Case 5:22-cv-07608	Document 1	Filed 12/02/22	Page 1 of 53				
1	Adam Alper (SBN: 196834) adam.alper@kirkland.com Akshay S. Deoras (SBN: 301962) akshay.deoras@kirkland.com KIRKLAND & ELLIS LLP 555 California Street San Francisco, CA 94104 Telephone: (415) 439-1400 Facsimile: (415) 439-1500							
2								
3								
4								
5								
6	Michael W. De Vries (SBN: 211001) michael.devries@kirkland.com KIRKLAND & ELLIS LLP 555 South Flower Street Los Angeles, CA 90071 Telephone: (213) 680-8400							
7								
8								
9	Facsimile: (213) 680-8500							
10	Leslie M. Schmidt (pending <i>pro hac vice</i>)							
11	leslie.schmidt@kirkland.com KIRKLAND & ELLIS LLP 601 Lexington Avenue New York, NY 10022 Telephone: (212) 446-4800							
12								
13	Facsimile: (212) 446-4900							
14	Kat Li (pending <i>pro hac vice</i>)							
15	kat.li@kirkland.com KIRKLAND & ELLIS LLP 401 Congress Avenue Austin, TX 78701							
16								
17	Telephone: (512) 678-9100 Facsimile: (512) 678-9101							
18	Attorneys for Plaintiff Apple Inc.							
19								
20	UNITED STATES DISTRICT COURT							
21	NORTHERN DISTRICT OF CALIFORNIA							
22								
23	APPLE INC.,		CASE NO.					
24	Plaintiff,		COMPLAINT F INFRINGEMEN					
25	V.		DEMAND FOR J					
26	ALIVECOR, INC.		DEMAND FOR J	UKI IKIAL				
27	Defendant.							
28]						

CASE NO. _____

This is an action about innovation and the opportunism and profiteering that threatens it.
 Apple Inc. ("Apple") is a global technology company that has, for decades, introduced cutting-edge,
 life-changing advancements in electronic healthcare that are relied upon by millions on a daily basis to
 better their lives.

6 2. Since its founding almost 50 years ago, Apple has held its place as an American and 7 worldwide leader by developing innovative technology, investing billions in domestic research and 8 development of technologies in a wide variety of industries, and producing devices and applications that 9 are at the core of today's society. In particular, Apple has long been an industry leader in cutting-edge 10 electronic healthcare solutions and has invested its considerable expertise and creativity in developing 11 such systems and bringing them to the public.

3. Among such advances, Apple has developed and patented a wide array of novel health 12 and fitness technologies, each of which provides users with accurate and highly accessible technology-13 powered insights empowering them to live a healthier life.¹ These include numerous critical, ground-14 breaking ECG technologies provided by the Apple Watch and watchOS. Apple began developing and 15 patenting these technologies over a decade ago. For example, in 2008, Apple had already developed and 16 filed for patent protection on specific and foundational technologies pertaining to embedded heart rate 17 and electric cardiac activity monitors. Apple's massive commitments to innovation in the healthcare 18 industry led to critical developments in key technologies, including those related to sensing irregular 19 heart rhythms that may be suggestive of atrial fibrillation (AFib), capturing an electrocardiogram 20("ECG" or "EKG"),² cycle tracking features for women (watchOS 6),³ blood oxygen saturation 21

22

1

See Exhibit 1, "How Apple Is Empowering People With Their Health Information," (July 20, 2022), https://www.apple.com/newsroom/2022/07/how-apple-is-empowering-people-with-their-health-information.

²⁵ 2 See Exhibit 2, "Apple Watch Series 4: Beautifully redesigned with breakthrough communication, and health capabilities," (Sept. fitness 12. 2018), 26 https://www.apple.com/newsroom/2018/09/redesigned-apple-watch-series-4-revolutionizescommunication-fitness-and-health; see also Exhibit 3, "ECG app and irregular heart rhythm notification available today on Apple Watch," (Dec. 6, 2018), available at 27 https://www.apple.com/newsroom/2018/12/ecg-app-and-irregular-heart-rhythm-notification-28 available-today-on-apple-watch/.

Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 3 of 53

measurement (watchOS 7),⁴ respiratory tracking during sleep, and fall detection (watchOS 8),⁵ to name 1 2 just a few. These advancements also include an integrated sensor in an electronic device that can 3 measure a user's heartbeat, heartrate, and other signals generated by the user's heart, which are the 4 subjects of the '257 patent-in-suit. Apple also improved upon this design with sealed button systems, 5 which are the subjects of the '619 patent-in-suit, as well as user interfaces for monitoring such health 6 data, which are the subjects of the '533 patent-in-suit. Apple also developed the ability to aggregate 7 such data for a user's healthcare providers to review, which is the subject of the '898 patent-in-suit. It is 8 innovations such as these and the millions of dollars Apple invested in the research and development of 9 these innovations—including the many features surrounding the Apple Watch and Apple's Health 10 App-that have bettered the lives of millions who use Apple's healthcare devices and pioneered the 11 personal health advancements that AliveCor attempts to co-opt through its litigation campaign against 12 Apple.

13 4. This case is about a far different story involving AliveCor, Inc. ("AliveCor") and its 14 brazen infringement of Apple's technology-technology that Apple developed years before AliveCor 15 even came into existence. Founded in 2010, AliveCor's business has focused on the sale of portable 16 ECG devices which rely on numerous technologies in Apple's iPhone and/or Watch to provide ECG 17 information to AliveCor's customers. Rather than develop its technology from scratch, however, 18 AliveCor resorted to including the very technology that Apple created and patented. This was no accident: AliveCor has long known of Apple's patented technology, as many of AliveCor's own patents 19 20 cite to many of Apple's patented innovations.

21

22

23

24

25

5. But AliveCor's business has not been commercially successful, and has instead been propped up by funding from private investors. AliveCor has responded to its own failures in the market

³ See Exhibit 4, "WatchOS 6 Advances Health And Fitness Capabilities for Apple Watch," (June 3, 2019), https://www.apple.com/newsroom/2019/06/watchos-6-advances-health-and-fitness-capabilities-for-apple-watch.

28 ⁵ See Exhibit 6, "WatchOS 8 Is Available Today," (Sept. 20, 2021), https://www.apple.com/newsroom/2021/09/watchos-8-is-available-today.

 ⁴ See Exhibit 5, "Apple Watch Series 6 Delivers Breakthrough Wellness And Fitness Capabilities," (Sept. 15, 2020), https://www.apple.com/newsroom/2020/09/apple-watch-series-6-delivers-breakthrough-wellness-and-fitness-capabilities.

Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 4 of 53

1 through opportunistic assertions of its patents against Apple. For example, AliveCor filed a complaint 2 before the International Trade Commission ("Commission"), seeking to stop Apple from importing its 3 products into the United States based on its assertion of patents covering unimportant alleged improvements to ECG devices.⁶ And while an Administrative Law Judge issued an Initial 4 5 Determination in that action finding a violation—a finding that Apple is presently contesting before the 6 Commission—Apple now brings this action to set the record straight as to who is the real pioneer and to 7 stop AliveCor's rampant infringement that unlawfully appropriates Apple's intellectual property. Apple 8 is the pioneering innovator, having researched, developed, and patented core, foundational technologies 9 before AliveCor came into existence. AliveCor's litigation campaign is nothing more than an attempt to 10 siphon from the success of Apple technologies it did not invent, all the while selling products that rely 11 on foundational ECG innovations that Apple patented years before AliveCor came to be.

12

17

NATURE OF THE CASE

6. Apple brings claims under the patent laws of the United States, 35 U.S.C. § 1, *et seq.*, for
the infringement of the following United States patents: U.S. Patent Nos. 10,076,257 (the "257
Patent"); 10,270,898 (the "898 Patent"); 10,866,619 (the "619 Patent"); and 10,568,533 (the "533
Patent") (collectively, the "Asserted Patents").

PARTIES

7. Apple is an American technology company organized under the laws of California,
having its principal place of business at One Apple Park Way, Cupertino, CA 95014. From its founding
in 1976, Apple has been the renowned global leader in consumer electronics products, including being
among the first manufacturers of personal computers, and later expanding into other technologies,
pioneering smart mobile communication devices, digital music players, notebooks, and wearables, as
well as related software, services, accessories, and networking solutions.

8. AliveCor is a company organized and existing under the laws of Delaware with its
principal place of business at 444 Castro Street, Suite 600, Mountain View, CA 94041.

²⁷
⁶ In re Certain Wearable Elec. Devices with ECG Functionality and Components Thereof, Inv. No. 337-TA-1266 (USITC). AliveCor also initiated a district court suit against Apple, AliveCor, Inc. v. Apple, Inc., C.A. No. 6:20-cv-1112 (W.D. Tex. 2021), which is currently stayed.

Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 5 of 53

JURISDICTION AND VENUE

9. This civil action asserts claims arising under the Patent Laws of the United States, 35
U.S.C. § 1 *et seq*. This Court therefore has subject matter jurisdiction over this action pursuant to 28
U.S.C. §§ 1331 and 1338(a).

10. The Court has personal jurisdiction over AliveCor because AliveCor maintains its 5 principal place of business in this District at 444 Castro Street, Suite 600, Mountain View, CA 94041, 6 and from that location conducts and/or directs the acts accused of infringement in this action. Moreover, 7 AliveCor conducts business in this District by shipping, distributing, offering for sale, selling, and 8 advertising (including the provision of an interactive web page) its products and services in both the 9 State of California and in this District. AliveCor has, either directly or through intermediaries, 10 purposefully and voluntarily placed one or more of its infringing products and/or services into the 11 stream of commerce with the intention and expectation that they will be purchased and used by 12 customers in this District. 13

14 11. Venue is proper in this District pursuant to 28 U.S.C. §§ 1391 and 1400(b) because
15 AliveCor regularly conducts business within this District, has a regular and established place of business
16 in this District, and has committed acts of infringement within this District.

17

1

2

3

4

18

APPLE'S PATENTED TECHNOLOGIES

The '257 Patent

19 12. The '257 Patent is titled "Seamlessly Embedded Heart Rate Monitor" and duly and
20 legally issued on September 18. 2018. The '257 Patent issued from U.S. Patent Application Serial No.
21 14/136,658 filed on December 20, 2013. A true and accurate copy of the '257 Patent is attached hereto
22 as Exhibit 7.

Apple is the owner, by valid assignment, of the entire right, title, and interest in and to the
'257 Patent. Prior to issuance, the '257 Patent inventors assigned all right, title, and interest in U.S.
Patent Application Serial No. 14/136,658 to Apple. This assignment is recorded at the United States
Patent and Trademark Office ("USPTO") at Reel/Frame 022149/0581 and a true and accurate copy is
attached hereto as Exhibit 8.

28

14. The '257 Patent is valid, enforceable, and is currently in full force and effect.

Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 6 of 53

The '898 Patent

15. The '898 Patent is titled "Wellness Aggregator" and duly and legally issued on April 23,
2019. The '898 Patent issued from U.S. Patent Application Serial No. 14/599,424 filed on January 16,
2015. A true and accurate copy of the '898 Patent is attached hereto as Exhibit 9.

Apple is the owner, by valid assignment, of the entire right, title, and interest in and to the
'898 Patent. Prior to issuance, the '898 Patent inventors assigned all right, title, and interest in U.S.
Patent Application Serial No. 14/599,424 to Apple. This assignment is recorded at the USPTO at
Reel/Frame 036850/0376 and a true and accurate copy is attached hereto as Exhibit 10.

9

1

2

3

4

10

17. The '898 Patent is valid, enforceable, and is currently in full force and effect.

The '619 Patent

11 18. The '619 Patent is titled "Electronic Device Having Sealed Button Biometric Sensing 12 System" and duly and legally issued on December 15, 2020. The '619 Patent issued from U.S. Patent 13 Application Serial No. 15/627,336 filed on June 19, 2017. A true and accurate copy of the '619 Patent 14 is attached hereto as Exhibit 11.

15 19. Apple is the owner, by valid assignment, of the entire right, title, and interest in and to the
'619 Patent. Prior to issuance, the '619 Patent inventors assigned all right, title, and interest in U.S.
Patent Application Serial No. 15/627,336 to Apple. This assignment is recorded at the USPTO at
Reel/Frame 042766/0554 and a true and accurate copy is attached hereto as Exhibit 12.

19

20

20. The '619 Patent is valid, enforceable, and is currently in full force and effect.

The '533 Patent

21 21. The '533 Patent is titled "User Interfaces For Health Monitoring" and duly and legally
22 issued on February 25, 2020. The '533 Patent issued from U.S. Patent Application Serial No.
23 16/143,959 filed on September 27, 2018. A true and accurate copy of the '533 Patent is attached hereto
24 as Exhibit 13.

25 22. Apple is the owner, by valid assignment, of the entire right, title, and interest in and to the
26 '533 Patent. Prior to issuance, the '533 Patent inventors assigned all right, title, and interest in U.S.
27 Patent Application Serial No. 16/143,959 to Apple. This assignment is recorded at the USPTO at
28 Reel/Frame 048113/0343 and a true and accurate copy is attached hereto as Exhibit 14.

CASE NO.

23. The '533 Patent is

1

2

6

7

B. The '533 Patent is valid, enforceable, and is currently in full force and effect.

ACCUSED PRODUCTS

3 24. The accused products in this case include, but are not limited to, AliveCor's
4 KardiaMobile Card, KardiaMobile, KardiaMobile 6L, Kardia App, KardiaPro (including devices and
5 servers, and mobile applications), and KardiaCare products (collectively, the "Accused Products").

FIRST CAUSE OF ACTION

Infringement of the '257 Patent by AliveCor

8 25. Apple realleges and incorporates each of the allegations in Paragraphs 1–24 above as
9 though fully set forth herein.

10 26. The '257 Patent, titled "Seamlessly Embedded Heart Rate Monitor," discloses a novel device that detects a user heartbeat or heart rhythm to provide electrocardiogram (EKG) data with 11 12 specific and concrete advantages over prior biometric devices. Exhibit 7 ('257 Patent), 1:52-63. The 13 '257 Patent explains that prior-art systems were not aesthetically pleasing and were difficult to use, 14 because they required additional actions beyond biometric reading. Id., 1:58-2:3. Accordingly, the 15 ²257 Patent claims a specific structure of an electronic device comprising an enclosure and heart sensor, 16 where the heart sensor includes "a first lead comprising a first pad that is embedded in a first portion of 17 the enclosure, wherein an exterior surface of the enclosure comprises an exterior surface of the first 18 portion, wherein the first pad is positioned underneath the exterior surface of the first portion" and "a 19 second lead comprising a second pad that is embedded in a second portion of the enclosure." Id., cl. 1. 20 Further, "the first pad is configured to detect a first electrical signal of the user's cardiac signal via the 21 user's skin's contact with the exterior surface of the first portion of the enclosure," and "the second pad 22 is configured to detect a second electrical signal of the user's cardiac signal via the user's skin's contact 23 with at least one of the second pad and the second portion of the enclosure." Id. The enclosure further 24 contains a processor configured to receive electrical signals detected by the first and second pads. *Id.*


25 26 27. AliveCor's products and/or services that infringe the '257 Patent include, but are not limited to, the KardiaMobile, KardiaMobile 6L, KardiaMobile Card, the Kardia App, and use thereof.

27 28. AliveCor makes, uses, sells, offers for sale, and/or imports the Accused Products and
28 components thereof in the United States.

1 29. AliveCor directly infringes—literally and/or under the doctrine of equivalents—at least 2 Claim 1 of the '257 Patent by making, using, selling, offering for sale, and/or importing into the United 3 States its Accused Products and components thereof. 4 30. For example, Claim 1 of the '257 Patent recites: 5 1. An electronic device for detecting a user's cardiac signal, comprising: 6 an enclosure: 7 a heart sensor configured to detect the user's cardiac signal, the heart sensor comprising: 8 a first lead comprising a first pad that is embedded in a first portion of the 9 enclosure, wherein an exterior surface of the enclosure comprises an exterior surface of the first portion, wherein the first pad is positioned 10 underneath the exterior surface of the first portion, and wherein the first pad is configured to detect a first electrical signal of the user's cardiac 11 signal via the user's skin's contact with the exterior surface of the first portion of the enclosure; and 12 a second lead comprising a second pad that is embedded in a second 13 portion of the enclosure, wherein the second pad is configured to detect a second electrical signal of the user's cardiac signal via the user's skin's 14 contact with at least one of the second pad and the second portion of the enclosure: and 15 a processor coupled to the heart sensor and configured to receive and process the 16 detected cardiac signal, wherein the first lead further comprises a first connector coupled to the first pad and configured to provide the first electrical signal 17 detected by the first pad to the processor, and wherein the second lead further comprises a second connector coupled to the second pad and configured to 18 provide the second electrical signal detected by the second pad to the processor. 19 31. The Accused Products practice each limitation of Claim 1 of the '257 Patent. 20 32. To the extent the preamble is construed to be limiting, AliveCor, at least when using the 21 Accused Products, practices "an electronic device for detecting a user's cardiac signal." See, e.g., 22 Exhibit 15 (KardiaMobile 6L IFU, https://www.kardia.com/assets/old/ifus/kardiamobile6l/19LB65.02-23 en.pdf); Exhibit 16 (KardiaMobile IFU, https://www.kardia.com/assets/old/ifus/kardiamobile/02LB49.6-24 en.pdf); Exhibit 17 (KardiaMobile Card IFU, https://www.alivecor.com/ifus/kardiamobile-25 card/21LB01.2-en.pdf). 26 27 28




6-Lead EKG





CASE NO.



INTENDED USE The KardiaMobile System is intended to record, store and transfer

single-channel electrocardiogram (ECG) rhythms. The KardiaMobile System also displays ECG rhythms and output of ECG analysis from AliveCor's KardiaAl platform including detecting the presence of normal sinus rhythm, atrial fibrillation, bradycardia, tachycardia, and others. The KardiaMobile System is intended for use by healthcare professionals, patients with known or suspected heart conditions and health conscious individuals. The device has not been tested and is not intended for pediatric use.

Features & Functionality

KardiaMobile Card is a personal EKG device that is capable of recording a Single-Lead EKG. It has two electrodes on the top surface and is powered by a non-replaceable battery. Bluetooth is used to wirelessly transmit EKG data from the device to your smartphone or tablet.

35. AliveCor, at least when using the Accused Products, practices a heart sensor comprising 14 15 "a first lead comprising a first pad that is embedded in a first portion of the enclosure, wherein an exterior surface of the enclosure comprises an exterior surface of the first portion, wherein the first pad 16 17 is positioned underneath the exterior surface of the first portion, and wherein the first pad is configured to detect a first electrical signal of the user's cardiac signal via the user's skin's contact with the exterior 18 19 surface of the first portion of the enclosure." These components are depicted in the images below. See Exhibit 18 (KardiaMobile 6L Store Front); Exhibit 19 (KardiaMobile Store Front); Exhibit 20 20 (KardiaMobile Card Store Front). 21

22 23 24

1

2

3

4

5

6

7

8

9

10

11

12

13


25 26


27 28 First lead

enclosure

comprising first conductive pad


embedded in a first portion of the





Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 13 of 53

the second pad is configured to detect a second electrical signal of the user's cardiac signal via the user's skin's contact with at least one of the second pad and the second portion of the enclosure." These components are depicted in the images below. *See* Exhibit 18 (KardiaMobile 6L Store Front); Exhibit 19 (KardiaMobile Store Front); Exhibit 20 (KardiaMobile Card Store Front).



13


1

2

3

Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 14 of 53

further comprises a first connector coupled to the first pad and configured to provide the first electrical signal detected by the first pad to the processor, and wherein the second lead further comprises a second connector coupled to the second pad and configured to provide the second electrical signal detected by the second pad to the processor." This component is depicted in the images below. *See* Exhibit 21 (circuitry images).





38. Each claim in the '257 Patent recites an independent invention. Neither Claim 1, described above, nor any other individual claim is representative of all claims in the '257 Patent.

9 39. AliveCor has been aware of the '257 Patent since at least the filing date of this
10 Complaint.

40. AliveCor has actively induced infringement of at least Claim 1 of the '257 Patent since at least the filing date of this Complaint, in violation of 35 U.S.C. § 271(b).

41. AliveCor's customers and end-users of the Accused Products directly infringe Claim 1 of the '257 Patent, at least by using the Accused Products, as described above in Paragraphs 32–39.

42. Since at least the filing date of this Complaint AliveCor knowingly induces infringement of at least Claim 1 of the '257 Patent by customers and end-users of the Accused Products with specific intent to induce infringement, and/or with willful blindness to the possibility that its acts induce infringement, through activities relating to selling, marketing, advertising, promotion, support, and distribution of the Accused Products in the United States.

43. AliveCor instructs customers and end-users, at least through its marketing, promotional, 20 and instructional materials, to use the infringing Accused Products, as described in detail above in 21 Paragraphs 32–39. AliveCor creates and distributes promotional and product literature for the Accused 22 Products that is designed to instruct, encourage, enable, and facilitate the user of the Accused Products 23 in a manner that directly infringes the Asserted Patents. In particular, AliveCor instructs end users on 24 how to use its products to sense heart conditions by using the first and second leads to detect electrical 25 signals using the processor of the devices. See, e.g., Exhibit 15 (KardiaMobile 6L IFU); Exhibit 16 26 (KardiaMobile System IFU); Exhibit 17 (KardiaMobile Card IFU); Exhibit 23 ("Setting up your Kardia 27 account," (2020), https://alivecor.zendesk.com/hc/en-us/articles/1500000111761); Exhibit 24 ("Setting 28

1

2

3

4

5

6

7

8

11

12

13

14

15

16

17

18

Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 16 of 53

1 up your KardiaMobile," (2020), https://alivecor.zendesk.com/hc/en-us/articles/360001941227); Exhibit 2 25 ("Setting KardiaMobile 6L," (2020),https://alivecor.zendesk.com/hc/enup your 3 us/articles/1500000113821); Exhibit 20 (KardiaMobile Card, 4 https://store.kardia.com/products/kardiamobile-card); Exhibit 18 (KardiaMobile 6L. 5 19 https://store.kardia.com/products/kardiamobile6l); Exhibit (KardiaMobile, 6 https://store.kardia.com/products/kardiamobile).

44. AliveCor provides its customers and end-users with additional instructions that direct the
customers and end-users to use the Accused Products in an infringing manner. Such instructions
include, for example, data sheets, technical specifications, customer support services, product sheets,
and technical support services.

45. AliveCor contributed and is contributing to infringement of at least Claim 1 of the '257
Patent, in violation of 35 U.S.C. § 271(c).

46. AliveCor's customers and end-users of the Accused Products directly infringe Claim 1 of
the '257 Patent, at least by using the Accused Products, as described in detail above in Paragraphs 32–
39.

16 47. AliveCor contributes to infringement of the '257 Patent by offering to sell, selling, and 17 importing into the United States the Accused Products and components thereof, including, for example, 18 the Accused Products and associated software applications, firmware, and other services. Such 19 components are substantial, material parts of the claimed inventions of the '257 Patent and have no 20 substantial non-infringing use. The only use of AliveCor's Accused Products is using the first and 21 second leads of the devices to detect electrical signals to determine if a user has any heart conditions.

48. The Accused Products and associated software applications, firmware, and other services
supplied by AliveCor are especially made and especially adapted for use in infringing the '257 Patent
and are not staple articles or commodities of commerce suitable for substantial non-infringing use.

25

49. AliveCor's infringement of the '257 Patent is without license or other authorization.

26 50. AliveCor's continued infringement of the '257 Patent has damaged and will continue to
27 damage Apple.

28

CASE NO.

Unless and until enjoined by this Court, AliveCor will continue to directly infringe as
 well as induce and contribute to infringement of the '257 Patent. AliveCor's infringing acts are causing
 and will continue to cause Apple at least irreparable harm, for which there is no adequate remedy at law.
 Under 35 U.S.C. § 283, Apple is entitled to a permanent injunction against further infringement.

5 52. This case is exceptional, entitling Apple to an award of attorney's fees and costs incurred
6 in prosecuting this action under 35 U.S.C. § 285.

7 8

SECOND CAUSE OF ACTION

Infringement of the '619 Patent by AliveCor

9 53. Apple realleges and incorporates each of the allegations in Paragraphs 1–52 above as
10 though fully set forth herein.

11 54. The '619 Patent discloses a novel device with specific and concrete manufacturing 12 improvements to prevent liquid or other contaminants from damaging the internal electronics, including 13 the use of a seal and a flexible conduit to transmit electrical signals from the biometric sensors to the 14 processor. Exhibit 11 ('619 Patent), 1:14–22, 1:26–40.

15 55. AliveCor's products and/or services that infringe the '619 Patent include, but are not
16 limited to, the KardiaMobile Card, the Kardia App, and use thereof.

17 56. AliveCor makes, uses, sells, offers for sale, and/or imports the Accused Products and
18 components thereof in the United States.

19 57. AliveCor directly infringes—literally and/or under the doctrine of equivalents—at least
20 Claim 1 of the '619 Patent at least by making, using, selling, offering for sale, and/or importing its
21 Accused Products and components thereof in the United States.

22 ||

23

24

25

26

27

28

58. For example, Claim 1 of the '619 patent recites:

1. An electronic device comprising:

an enclosure having an enclosed volume and an opening formed in a sidewall;

a processor positioned in the enclosed volume;

a button assembly within the opening, the button assembly comprising:

an input member having an input surface; and

	Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 18 of 53			
1 2	a biometric sensor positioned below the input member and configured to produce an output signal in response to a touch on the input surface, the output signal corresponding to a biometric characteristic;			
3	a seal positioned between a sealing surface of the button assembly and the enclosure; and			
4 5	a flexible conduit coupled to the biometric sensor and configured to transmit the output signal to the processor; wherein:			
6	a portion of the flexible conduit is sandwiched between the seal and the sealing surface or between the seal and the enclosure.			
7	59. The Accused Products practice each limitation of Claim 1 of the '619 Patent.			
8	60. To the extent the preamble is construed to be limiting, AliveCor, at least when using the			
9	Accused Products, practices "an electronic device." See, e.g., Exhibit 20 (KardiaMobile Card Store			
10	Front, https://store.kardia.com/products/kardiamobile-card); Exhibit 17 (KardiaMobile Card Instructions			
11	For Use, https://www.alivecor.com/ifus/kardiamobile-card/21LB01.2-en.pdf).			
12				
13	Recording Single-Lead EKG X			
14 15				
16				
17	AliveCor KardiaMobile			
18				
10				
20				
21				
22				
23	Features & Functionality			
24	KardiaMobile Card is a personal EKG device that is capable of recording a Single-Lead EKG. It			
25	has two electrodes on the top surface and is powered by a non-replaceable battery. Bluetooth is used to wirelessly transmit EKG data from the device to your smartphone or tablet.			
26	61. AliveCor, at least when using the Accused Products, practices "an enclosure having an			
27	enclosed volume and an opening formed in a sidewall" as required by Claim 1 of the '619 Patent. This			
28				

Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 19 of 53

component is depicted in the images below. *See, e.g.*, Exhibit 20 (KardiaMobile Card Store Front, https://store.kardia.com/products/kardiamobile-card); Exhibit 21 (circuitry images).



62. AliveCor, at least when using the Accused Products, practices "a processor positioned in the enclosed volume" as required by Claim 1 of the '619 Patent. This component is depicted in the image below showing the KardiaMobile Card. Exhibit 21 (circuitry images).

28

25

26

27

1




63. AliveCor, at least when using the Accused Products, practices "a button assembly within the opening, the button assembly comprising: an input member having an input surface; and a biometric sensor positioned below the input member and configured to produce an output signal in response to a touch on the input surface, the output signal corresponding to a biometric characteristic" as required by Claim 1 of the '619 Patent. For instance, the '619 Patent indicates that the claimed "button assembly" may be "stationary" and/or a "touch sensor to detect user input." *See* Exhibit 11 ('619 Patent), 2:23–24, 4:29–38, 5:14–22, 6:49–59. These components are depicted in the images below. *See, e.g.*, Exhibit 20 (KardiaMobile Card Store Front, https://store.kardia.com/products/kardiamobile-card).



64. AliveCor, at least when using the Accused Products, practices "a seal positioned between a sealing surface of the button assembly and the enclosure" as required by Claim 1 of the '619 Patent. *See, e.g.*, Exhibit 17 (KardiaMobile Card IFU) at 12.


Ingress Protection Marking

KardiaMobile Card is IPX8 rated. KardiaMobile Card is protected against immersion in water up to 2 meters for 1 hour. KardiaMobile Card has been tested with relevant requirement standard IEC 60601-1-11:2015.



65. AliveCor, at least when using the Accused Products, practices "a flexible conduit coupled to the biometric sensor and configured to transmit the output signal to the processor" as required by Claim 1 of the '619 Patent. These components are depicted in the images of the KardiaMobile Card below.





Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 23 of 53

Each claim in the '619 Patent recites an independent invention. Neither Claim 1,
 described above, nor any other individual claim is representative of all claims in the '619 Patent.

3 68. AliveCor has been aware of the '619 Patent since at least the filing date of this4 Complaint.

69. AliveCor has actively induced infringement of at least Claim 1 of the '619 Patent since at
least the filing date of this Complaint, in violation of 35 U.S.C. § 271(b).

7 70. AliveCor's customers and end-users of the Accused Products directly infringe Claim 1 of
8 the '619 Patent, at least by using the Accused Products, as described above in Paragraphs 60–68.

- 9 71. Since at least the filing date of this Complaint AliveCor knowingly induces infringement 10 of at least Claim 1 of the '619 Patent by customers and end-users of the Accused Products with specific 11 intent to induce infringement, and/or with willful blindness to the possibility that its acts induce 12 infringement, through activities relating to selling, marketing, advertising, promotion, support, and 13 distribution of the Accused Products in the United States.
- AliveCor instructs customers and end-users, at least through its marketing, promotional,
 and instructional materials, to use the infringing Accused Products, as described in detail above in
 Paragraphs 60–68. AliveCor creates and distributes promotional and product literature for the Accused
 Products that is designed to instruct, encourage, enable, and facilitate the user of the Accused Products. *See, e.g.*, Exhibit 17 (KardiaMobile Card IFU); Exhibit 23 ("Setting up your Kardia account," (2020),
 https://alivecor.zendesk.com/hc/en-us/articles/1500000111761); Exhibit 20 (KardiaMobile Card,
 https://store.kardia.com/products/kardiamobile-card).

73. AliveCor provides its customers and end-users with additional instructions that direct the
customers and end-users to use the Accused Products in an infringing manner. Such instructions
include, for example, data sheets, technical specifications, customer support services, product sheets,
and technical support services.

25 74. AliveCor contributed and is contributing to infringement of at least Claim 1 of the '619
26 Patent, in violation of 35 U.S.C. § 271(c).

27

28

COMPLAINT

CASE NO.

Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 24 of 53

75. AliveCor's customers and end-users of the Accused Products directly infringe Claim 1 of
 the '619 Patent, at least by using the Accused Products, as described in detail above in Paragraphs 60–
 68.

AliveCor contributes to infringement of the '619 Patent by offering to sell, selling, and
importing into the United States the Accused Products and components thereof, including, for example,
the Accused Products and associated software applications, firmware, and other services. Such
components are substantial, material parts of the claimed inventions of the '619 Patent and have no
substantial non-infringing use.

9 77. The Accused Products and associated software applications, firmware, and other services
10 supplied by AliveCor are especially made and especially adapted for use in infringing the '619 Patent
11 and are not staple articles or commodities of commerce suitable for substantial non-infringing use.

12 ||

78.

AliveCor's infringement of the '619 Patent is without license or other authorization.

13 79. AliveCor's continued infringement of the '619 Patent has damaged and will continue to14 damage Apple.

15 80. Unless and until enjoined by this Court, AliveCor will continue to directly infringe as
16 well as induce and contribute to infringement of the '619 Patent. AliveCor's infringing acts are causing
17 and will continue to cause Apple at least irreparable harm, for which there is no adequate remedy at law.
18 Under 35 U.S.C. § 283, Apple is entitled to a permanent injunction against further infringement.

19 81. This case is exceptional, entitling Apple to an award of attorney's fees and costs incurred
20 in prosecuting this action under 35 U.S.C. § 285.

21

22

$, \parallel$

<u>THIRD CAUSE OF ACTION</u> Infringement of the '898 Patent by AliveCor

23 82. Apple realleges and incorporates each of the allegations in Paragraphs 1–81 above as
24 though fully set forth herein.

83. The '898 Patent discloses a novel method for securely measuring, storing, and sharing
wellness data through unique hardware and software—namely, that prior art systems did not allow the
analysis of multiple pieces of wellness data to be viewed and analyzed on one device. Exhibit 9 ('898
Patent), 1:40–47. The '898 patent is thus directed at novel ways for aggregating wellness data by

Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 25 of 53

1 granularly approving sources of healthcare data and approving destinations of that data. Id., 2:57–3:17. 2 The inventions disclosed in the '898 Patent specifically improve prior-art health applications by 3 providing new ways for users or healthcare providers to view and analyze wellness data collected from a 4 variety of sources. Id., 1:28–47. The specification provides exemplary embodiments providing novel 5 means to aggregate and display data based on user input. Id., 1:50-5:12. The claims are directed to specific and concrete methods of operating a healthcare-management system, including limitations on 6 how data is communicated—only between "approved sources" and "approved destinations"—and novel 7 8 ways to view wellness data that were unavailable before the '898 patent. For example, the claims 9 describe "display[ing] a detailed view of a sub-category of wellness data," where that detailed view 10 includes "a graph representation of the sub-category of wellness data that includes aggregated values of 11 the sub-category of wellness data." Id., cl. 1. Other claims describe specific techniques for analyzing 12 sources of wellness data with respect to each other, how access to the wellness information is restricted, 13 and how subcategories of data are created and analyzed.

14 84. AliveCor's products and/or services that infringe the '898 Patent include, but are not 15 limited to, the KardiaPro service, including the AliveCor server(s) hosting the service and devices 16 running the service, in conjunction with the KardiaMobile, KardiaMobile 6L, KardiaMobile Card, 17 and/or Kardia App; and use thereof.

18

85. AliveCor makes, uses, sells, offers for sale, and/or imports the Accused Products and 19 components thereof in the United States.

20 86. AliveCor directly infringes—literally and/or under the doctrine of equivalents—at least 21 Claim 1 of the '898 Patent, at least by making, using, selling, offering for sale, and/or importing its 22 Accused Products and components thereof in the United States.

23

24

25

26

27

28

87. For example, Claim 1 of the '898 Patent recites:

1. A non-transitory computer-readable storage medium storing one or more programs, the one or more programs comprising instructions, which when executed by an electronic device with a display, cause the device to:

receive information identifying a plurality of approved sources of wellness data, wherein the plurality of approved sources comprise an electronic device or software application;

	Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 26 of 53						
1 2	receive information identifying a plurality of approved destinations of wellness data, wherein the plurality of approved destinations comprise an electronic device						
3	or software application;						
4	display a detailed view of a sub-category of wellness data, the detailed view comprising:						
5	a graph representation of the sub-category of wellness data that includes						
6 7	aggregated values of the sub-category of wellness data, wherein the sub- category of wellness data is from the plurality of approved sources for the sub-category of wellness data; and						
8 9	a selectable data sharing option;						
9 10	receive user selection of the selectable data sharing option; and in response to receiving the selection of the selectable data sharing option,						
11	display:						
12 13	the plurality of approved sources for the sub-category of wellness data, wherein the sub-category of wellness data is approved to be received from the plurality of approved sources and stored in a wellness database; and						
14 15 16	the plurality of approved destinations for the sub-category of wellness data, wherein the sub-category of wellness data is approved to be accessed from the wellness database by the plurality of approved destinations of wellness data.						
17	88. AliveCor, at least when using the Accused Products, performs every step of Claim 1 of						
18	the '898 Patent.						
19	89. To the extent the preamble is construed to be limiting, AliveCor, at least when using the						
20	Accused Products, practices "[a] non-transitory computer-readable storage medium storing one or more						
21	programs, the one or more programs comprising instructions, which when executed by an electronic						
22	device with a display." For example, the Accused Products comprise instructions that are executed by						
23	electronic devices with a display. See, e.g., Exhibit 26						
24	(https://clinicians.alivecor.com/documents/AliveCor%20Inpatient%20User%20Guide.pdf).						
25							
26							
27							
28							
	COMPLAINT 26 CASE NO						

Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 27 of 53

KardiaPro	ECG Recording	Countrast ECG Patient 11- View Patient Tile	
(9)	Blake Smith Marris, R		
	Blake Smith More More DOI: 04-04-1946 of yrs oldy Sm: Male Sm: Male Sm: Male More Smith Sm: Connection Fund. II Sel-208 to 19-01-000	View Patient You an 25 mm/s 10 mm/mV	
Robert Morris	68 DPM - Recorded Today at 10:07 AM -	nuner	
Ihis Deshboerd	The second	Indulat	
Patients	Ilmon do and		
V ECE Interv	Il		
D	1 mm mm mm	the	
	In the second	mm	
Settings		TT I	

AliveCor, at least when using the Accused Products, practices "receiv[ing] information 90. 11 identifying a plurality of approved sources of wellness data, wherein the plurality of approved sources 12 comprise an electronic device or software application" as required by Claim 1 of the '898 Patent. For 13 14 example, KardiaPro receives wellness data including the user's cardiac signature and heartrate among 15 other things from the Accused Products and from QT analysis providers for a plurality of patients, as depicted in the images below. Patients approve sending these sources of data to clinicians by consenting 16 17 to sharing the data. See, e.g., Exhibit 26 (https://clinicians.alivecor.com/documents/AliveCor%20Inpatient%20User%20Guide.pdf); Exhibit 19 18 19 Exhibit (https://store.kardia.com/products/kardiamobile); 18 20 (https://store.kardia.com/products/kardiamobile61); Exhibit 20 (https://store.kardia.com/products/kardiamobile-card). 21 22 23 24

25 26

1

2

3

4

5

6


7

8

9

- 27
- 28

Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 28 of 53



91. AliveCor, at least when using the Accused Devices, practices "receiv[ing] information identifying a plurality of approved destinations of wellness data, wherein the plurality of approved destinations comprise an electronic device or software application," as required by Claim 1 of the '898 Patent. For example, clinicians who receive data from approved sources can share that data with approved destinations including a QT analysis partner and other clinicians. *See, e.g.*, Exhibit 26

24

25


26

27

28

Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 29 of 53

(https://clinicians.alivecor.com/documents/AliveCor%20Inpatient%20User%20Guide.pdf); Exhibit 27 (https://www.kardia.com/professional/hcp).



1


Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 30 of 53


1


2

3

92. AliveCor, at least when using the Accused Products, practices "display[ing] a detailed view of a sub-category of wellness data," as required by Claim 1 of the '898 Patent. Exhibit 28 (https://clinicians.alivecor.com/our-solution).








	Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 33 of 53						
1 2 3 4 5 6		Reviewing ECGs, continued (Interpretation Workflow) AFTER SAVING YOUR INTERPRETATION, YOU CAN EITHE Select "Reassign" to send ECG to a different KardiaPro Inbox for review. The user must have a user account in your organization's KardiaPro account.	3				
7	96. AliveCor, at least when using the Accused Products, practices "receiv[ing] user selection						
8	of the selectable data sharing option" as required by Claim 1 of the '898 Patent. For example, the						
9	Accused Products, upon co	llecting patients' data, allow a clinician t	to share the data with approved				
10	destinations.	See, e.g.,	Exhibit 26				
11	(https://clinicians.alivecor.com/documents/AliveCor%20Inpatient%20User%20Guide.pdf).						
12							
13	SETUP	RECORDING an ECG	ACCESSING ECG and QT RESULTS				
14		QT Anal	ysis requests QT Analysis partner				
15 16 17 18		or KardiaStation on your mobile phones or tablets	OT Analysis results				
19							
20	One KardiaMobile 6L per patient		KardiaPro portal				
20							
22	Reviewing ECGs, continued (Interpretation Workflow)						
23 24		AFTER SAVING YOUR INTERPRETATION, YOU CAN EITHER					
24		Select "Reassign" to send ECG to a different					
26		KardiaPro Inbox for review. The user must have a user account in your organization's KardiaPro account.					
27	97. AliveCor, at	least when using the Accused Products, pr	actices "in response to receiving				
28	the selection of the selectable data sharing option, display[ing]: the plurality of approved sources for the						
	Complaint	33	CASE NO				


Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 34 of 53

1


sub-category of wellness data, wherein the sub-category of wellness data is approved to be received 2 from the plurality of approved sources and stored in a wellness database" as required by Claim 1 of the 3 '898 Patent. For example, the Accused Products, upon collecting patients' data, display a plurality of 4 approved sources of patients' data for a clinician to share with approved destinations. See, e.g., Exhibit 5 26 (https://clinicians.alivecor.com/documents/AliveCor%20Inpatient%20User%20Guide.pdf).



Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 35 of 53




Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 36 of 53




Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 37 of 53 1 Reviewing ECGs, continued (Interpretation Workflow) 2 3 AFTER SAVING YOUR INTERPRETATION, YOU CAN EITHER 4 Select "Reassign" to send ECG to a different KardiaPro Inbox for review. The user must have 5 a user account in your organization's KardiaPro account. 6 99. AliveCor, at least when using the Accused Products, practices "the plurality of approved 7 destinations for the sub-category of wellness data, wherein the sub-category of wellness data is approved 8 to be accessed from the wellness database by the plurality of approved destinations of wellness data" as 9 required by Claim 1 of the '898 Patent. For example, the Accused Products, upon collecting patients' 10 data, display a plurality of approved sources of patients' data and allow a clinician to share a patient's 11 particular sub-category of approved wellness data with approved destinations. See, e.g., Exhibit 28 12

(https://clinicians.alivecor.com/our-solution).



Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 38 of 53



Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 39 of 53

103. AliveCor's customers and end-users of the Accused Products directly infringe Claim 1 of the '898 Patent, at least by using the Accused Products, as described above in Paragraphs 89–101.

2

1

3 104. Since at least the filing date of this Complaint, AliveCor knowingly induces infringement
4 of at least Claim 1 of the '898 Patent by customers and end-users of the Accused Products with specific
5 intent to induce infringement, and/or with willful blindness to the possibility that its acts induce
6 infringement, through activities relating to selling, marketing, advertising, promotion, support, and
7 distribution of the Accused Products in the United States.

8 AliveCor instructs customers and end-users, at least through its marketing, promotional, 105. 9 and instructional materials, to use the infringing Accused Products, as described in detail above in 10 Paragraphs 89–101. AliveCor creates and distributes promotional and product literature for the Accused 11 Products that is designed to instruct, encourage, enable, and facilitate the user of the Accused Products 12 in a manner that directly infringes the Asserted Patents. For example, AliveCor instructs users on how 13 to use its products to detect a heart condition, specifically instructs users not to move when taking a 14 heart measurement, and further instructs users on how to access and use the Kardia App dashboard. 15 AliveCor also instructs users how to use its KardiaCare service to automatically translate healthcare 16 information, including information regarding a care event, to a user's family. See, e.g., Exhibit 15 17 (KardiaMobile 6L IFU); Exhibit 16 (KardiaMobile System IFU); Exhibit 17 (KardiaMobile Card IFU); 18 Exhibit 23 ("Setting up your Kardia account," (2020), https://alivecor.zendesk.com/hc/en-19 us/articles/1500000111761); Exhibit 24 ("Setting up your KardiaMobile," (2020),20 https://alivecor.zendesk.com/hc/en-us/articles/360001941227); Exhibit 25 ("Setting up your 21 KardiaMobile 6L," (2020), https://alivecor.zendesk.com/hc/en-us/articles/1500000113821); Exhibit 20 22 (KardiaMobile Card, https://store.kardia.com/products/kardiamobile-card); Exhibit 18 (KardiaMobile 23 6L, https://store.kardia.com/products/kardiamobile6l); Exhibit 19 (KardiaMobile, https://store.kardia.com/products/kardiamobile); 24 Exhibit 29 (https://kssahsn.net/wp-25 content/uploads/2020/05/KardiaMobile-Remote-ECG-COVID-19-.pdf); Exhibit 30 26 (https://clinicaltrials.gov/ct2/show/results/NCT03557034).

27 106. AliveCor provides its customers and end-users with additional instructions that direct the
28 customers and end-users to use the Accused Products in an infringing manner. Such instructions

Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 40 of 53

include, for example, data sheets, technical specifications, customer support services, product sheets, and technical support services.

3 107. AliveCor contributed and is contributing to infringement of at least Claim 1 of the '898
4 Patent, in violation of 35 U.S.C. § 271(c).

5 108. AliveCor's customers and end-users of the Accused Products directly infringe Claim 1 of
6 the '898 Patent, at least by using the Accused Products, as described in detail above in Paragraphs 89–
7 101.

8 109. AliveCor contributes to infringement of the '898 Patent by offering to sell, selling, and 9 importing into the United States the Accused Products and components thereof, including, for example, 10 the Accused Products and associated software applications, firmware, and other services. Such 11 components are substantial, material parts of the claimed inventions of the '898 Patent and have no 12 substantial non-infringing use. For example, AliveCor's Accused Products are designed to detect a 13 cardiac care event and have no other substantial use. Further, AliveCor's KardiaCare service is 14 designed to send a user's care event results to a third party automatically and make such information 15 available to clinicians, and there are no substantial non-infringing uses associated with the KardiaCare 16 service.

17 110. The Accused Products and associated software applications, firmware, and other services
18 supplied by AliveCor are especially made and especially adapted for use in infringing the '898 Patent
19 and are not staple articles or commodities of commerce suitable for substantial non-infringing use.

20

1

2

111. AliveCor's infringement of the '898 Patent is without license or other authorization.

21 112. AliveCor's continued infringement of the '898 Patent has damaged and will continue to
22 damage Apple.

113. Unless and until enjoined by this Court, AliveCor will continue to directly infringe as
well as induce and contribute to infringement of the '898 Patent. AliveCor's infringing acts are causing
and will continue to cause Apple at least irreparable harm, for which there is no adequate remedy at law.
Under 35 U.S.C. § 283, Apple is entitled to a permanent injunction against further infringement.

27 114. This case is exceptional, entitling Apple to an award of attorney's fees and costs incurred
28 in prosecuting this action under 35 U.S.C. § 285.

40

FOURTH CAUSE OF ACTION

Infringement of the '533 Patent by AliveCor

115. Apple realleges and incorporates each of the allegations in Paragraphs 1–114 above as though fully set forth herein.

The '533 Patent discloses novel devices and methods for receiving inputs and displaying 116. 5 tutorials for measuring biometric data and responding to the interruption of a measurement. In 6 particular, the patent discloses unique hardware and software capable of using inventive user interface 7 technology to guide patients through the measurement process, and specifically provides concrete 8 techniques to solve the problems of improper measurements. The novel features disclosed in the '533 9 Patent improve upon prior-art techniques for managing health monitoring that the patent describes "are 10 generally cumbersome and inefficient" and "time-consuming." Exhibit 13 ('533 Patent), 1:45-52. 11 Specifically, the '533 Patent teaches devices with "faster, more efficient methods and interfaces" for 12 managing health monitoring that increase "the effectiveness, efficiency, and user satisfaction with such 13 devices." Id., 10:34–39. For example, the claims require a specific type of user interface to be shown to 14 record biometric information. Id., cl. 1. The claims next provide innovative solutions to the problem of 15 an interrupted biometric recording by displaying a "second user interface" when the "first criteria"-the 16 biometric input to the device-is no longer met. Id. This is a unique problem arising in automatic 17 biometric systems such as the one claimed in the patent and used by AliveCor. As the '533 patent 18 explains, certain computing algorithms that detect biometric conditions require sufficient sample sizes of 19 measurements to provide an evaluation; before the '533 patent, there was no efficient way to ensure that 20 a user's sample size was sufficient. Id., 34:28-42. Moreover, the patent provides another period of time 21 to deal with other computing issues dealing with device inactivity, problems that existed without a 22 solution in the prior art. Id., cl. 1. 23

24 117. AliveCor's products and/or services that infringe the '533 Patent include, but are not
25 limited to, the KardiaMobile Card, the Kardia App, and use thereof.

26 118. AliveCor makes, uses, sells, offers for sale, and/or imports the Accused Products and
27 components thereof in the United States.

28

1

2

3

4

1 119. AliveCor directly infringes—literally and/or under the doctrine of equivalents—at least 2 Claim 20 of the '533 Patent, at least by making, using, selling, offering for sale, and/or importing its 3 Accused Products and components thereof in the United States 4 120. For example, Claim 20 of the '533 Patent recites: 5 20. A non-transitory computer-readable storage medium storing one or more programs configured to be executed by one or more processors of a first 6 electronic device with a display and one or more input devices including a biometric sensor, the one or more programs including instructions for: 7 displaying, on the display, a first user interface indicating that the first 8 electronic device is ready to detect biometric information; 9 detecting a first input with the biometric sensor that satisfies first criteria; 10 in response to detecting the first input with the biometric sensor: 11 starting to record biometric information detected by the biometric sensor: and 12 displaying, on the display, a second user interface that is different 13 from the first user interface, wherein the second user interface includes an indication of progress in recording the biometric 14 information: 15 after recording at least a portion of the biometric information, detecting, via the one or more input devices, that the first criteria are no longer met; 16 in response to detecting that the first criteria are no longer met for a first 17 period of time, resetting the indication of progress in recording the biometric information and maintaining display of the second user 18 interface; and 19 in response to detecting that the first criteria are no longer met for a second period of time that is longer than the first period of time, replacing 20 display of the second user interface with the first user interface. 21 121. AliveCor, at least when using the Accused Products, practices each limitation of Claim 22 20 of the '533 Patent. 23 122. To the extent the preamble is construed to be limiting, the Accused Products include a 24 "non-transitory computer readable storage medium storing one or more programs configured to be 25 executed by one or more processors of a first electronic device with a display and one or more input 26 devices including a biometric sensor." The Kardia App is a program configured to be executed by one 27 or more processors of a first electronic device with a display (e.g., a phone or tablet running at least 28


Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 43 of 53

1 Android OS 6.0) and one or more input devices including a biometric sensor (e.g., the KardiaMobile 2 Card). See, Exhibit 20 (KardiaMobile Card Store Front, e.g., 3 https://store.kardia.com/products/kardiamobile-card) ("KardiaMobile Card is compatible with most 4 popular phones and tablets. To use your Kardia device, you must download the Kardia app on a 5 compatible device running at least Apple iOS 10.3.3, or at least Android OS 6.0.") (emphasis in 6 original); Exhibit 31 (KardiaMobile Card Compatibility, https://alivecor.zendesk.com/hc/en-7 us/articles/1500000449521-Compatibility); Exhibit 20 (KardiaMobile Card Store Front. 8 https://store.kardia.com/products/kardiamobile-card).




123. The Accused Products include "one or more programs including instructions for: displaying, on the display, a first user interface indicating that the first electronic device is ready to detect biometric information." This is depicted in the image below. *See* Exhibit 22 (Kardia Mobile App screenshots).

9



	7:30 ≰ ♥ 曇 ●	¥ 🤝 II 16% 🕯		
	KardiaMobile Card	~ ×		
	• 30	2		
	врм	Battery		
	Turn on your KardiaM	obile Card		
	device Amber Light — Power I	Button		
	Alector	3		
	VIEW TUTORIA	L		
	CONTACT SUPPO	IRT		
	25mm/s, 10mm/m	V		
		<		
124. The Accused Pro	oducts include "one	or more p	rograms inclu	iding instructions
for detecting a first input with	the biometric sensor	that satisfies f	irst criteria."	This is depicted in
the image below. See Exhibit 17 (Kardia Mobile Card IF	[°] U).		




Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 46 of 53



126. The Accused Products include "one or more programs including instructions for ... in response to detecting the first input with the biometric sensor. . . displaying, on the display, a second user interface that is different from the first user interface, wherein the second user interface includes an indication of progress in recording the biometric information." This is depicted in the images below. See Exhibit (Kardia App screenshots); see also Exhibit (https://www.youtube.com/watch?v=eA9pv6TVr-c).




127. The Accused Products include "one or more programs including instructions for . . . after recording at least a portion of the biometric information, detecting, via the one or more input devices, that the first criteria are no longer met" and "in response to detecting that the first criteria are no longer met" and "in response to detecting that the first criteria are no longer met for a first period of time, resetting the indication of progress in recording the biometric information and maintaining display of the second user interface." This is depicted in the images below, which illustrate that the device detects a loss of a connection and determines that the first criteria are no longer met, resetting the progress indicator and maintaining the second user interface. *See* Exhibit 22 (Kardia App screenshots); *see also* Exhibit 32 (https://www.youtube.com/watch?v=eA9pv6TVr-c).



128. The Accused Products include "one or more programs including instructions for . . . in response to detecting that the first criteria are no longer met for a second period of time that is longer than the first period of time, replacing display of the second user interface with the first user interface." This is depicted in the images below, which occurs after a period of time longer than the period of time discussed in connection with the previous limitation. *See* Exhibit 22 (Kardia Mobile App screenshots).

COMPLAINT



7:30 & 🛚	æ • 🔴	▲ 弐 川 16%
•	Selected Device KardiaMobile Card	- ×
	врм 30	? Battery
	on your KardiaMo device ber Light Power B	utton
	VIEW TUTORIAL	
	CONTACT SUPPOR	
	25mm/s, 10mm/mV	<

129. Each claim in the '533 Patent recites an independent invention. Neither Claim 20, described above, nor any other individual claim is representative of all claims in the '533 Patent.

20 130. AliveCor has been aware of the '533 Patent since at least the filing date of this
21 Complaint.

131. AliveCor has actively induced infringement of at least Claim 20 of the '533 Patent since at least the filing date of this Complaint, in violation of 35 U.S.C. § 271(b).

24132. AliveCor's customers and end-users of the Accused Products directly infringe Claim 2025of the '533 Patent, at least by using the Accused Products, as described above in Paragraphs 122–30.

Since at least the filing date of this Complaint AliveCor knowingly induces infringement
 of at least Claim 20 of the '533 Patent by customers and end-users of the Accused Products with specific
 intent to induce infringement, and/or with willful blindness to the possibility that its acts induce

Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 50 of 53

infringement, through activities relating to selling, marketing, advertising, promotion, support, and
 distribution of the Accused Products in the United States.

_

AliveCor instructs customers and end-users, at least through its marketing, promotional, 3 134. 4 and instructional materials, to use the infringing Accused Products, as described in detail above in 5 Paragraphs 122–30. AliveCor creates and distributes promotional and product literature for the Accused Products that is designed to instruct, encourage, enable, and facilitate the user of the Accused Products 6 7 in a manner that directly infringes the Asserted Patents. In particular, AliveCor instructs end users on 8 how to use its products to capture biometric data alongside display prompts. See, e.g., Exhibit 17 9 (KardiaMobile Card IFU); Exhibit 23 ("Setting up your Kardia account," (2020), 10 https://alivecor.zendesk.com/hc/en-us/articles/1500000111761); Exhibit 20 (KardiaMobile Card, 11 https://store.kardia.com/products/kardiamobile-card).

12 135. AliveCor provides its customers and end-users with additional instructions that direct the
13 customers and end-users to use the Accused Products in an infringing manner. Such instructions
14 include, for example, data sheets, technical specifications, customer support services, product sheets,
15 and technical support services.

16 136. AliveCor contributed and is contributing to infringement of at least Claim 20 of the '533
17 Patent, in violation of 35 U.S.C. § 271(c).

18 137. AliveCor's customers and end-users of the Accused Products directly infringe Claim 20
19 of the '533 Patent, at least by using the Accused Products, as described in detail above in Paragraphs
20 122–30.

21 138. AliveCor contributes to infringement of the '533 Patent by offering to sell, selling, and 22 importing into the United States the Accused Products and components thereof, including, for example, 23 the Accused Products and associated software applications, firmware, and other services. Such 24 components are substantial, material parts of the claimed inventions of the '533 Patent and have no 25 substantial non-infringing use. The only use of AliveCor's Accused Products is using the first and 26 second leads of the devices to detect electrical signals to determine if a user has any heart conditions and 27 displaying such information on a user interface on a display of an electronic device, including as 28 directed by the Kardia App.

Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 51 of 53

1 139. The Accused Products and associated software applications, firmware, and other services
 2 supplied by AliveCor are especially made and especially adapted for use in infringing the '533 Patent
 3 and are not staple articles or commodities of commerce suitable for substantial non-infringing use.

4 ||

140. AliveCor's infringement of the '533 Patent is without license or other authorization.

5 141. AliveCor's continued infringement of the '533 Patent has damaged and will continue to
6 damage Apple.

142. Unless and until enjoined by this Court, AliveCor will continue to directly infringe as
well as induce and contribute to infringement of the '533 Patent. AliveCor's infringing acts are causing
and will continue to cause Apple at least irreparable harm, for which there is no adequate remedy at law.
Under 35 U.S.C. § 283, Apple is entitled to a permanent injunction against further infringement.

11 143. This case is exceptional, entitling Apple to an award of attorney's fees and costs incurred
12 in prosecuting this action under 35 U.S.C. § 285.

- 13
- 14

144.

15

Apple respectfully requests a jury trial on any issues so triable by right.

PRAYER FOR RELIEF

DEMAND FOR JURY TRIAL

16 145. WHEREFORE, Apple respectfully request that this Court enter judgment in their favor
17 and grant the following relief:

18

(i) a judgment that AliveCor infringes, directly and indirectly, the Asserted Patents;

19 (ii) an order permanently enjoining AliveCor, its affiliates and subsidiaries, and each of its 20 officers, agents, servants and employees and those acting in privity or concert with them, from making, 21 offering to sell, selling, using, or importing into the United States products claimed in any of the claims 22 of the Asserted Patents; using or performing methods claimed in any of the claims of the Asserted 23 Patents; inducing others to use and perform methods that infringe any claim of the Asserted Patents; 24 inducing others to make, offer, sell, use or import into the United States articles that infringe, or are 25 made by a process that infringes, any claim of the Asserted Patents; and contributing to others infringing any claim of the Asserted Patents, until after the expiration of the Asserted Patents, respectively, 26 27 including any extensions and/or additional periods of exclusivity to which Apple is or becomes entitled;

Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 52 of 53

1	(iii)	an order awarding damages under 35 U.S.C. §§ 154 & 284 in an amount sufficient to				
2	compensate A	apple for their damages arising from infringement by AliveCor, including, but not limited				
3	to, lost profits and/or a reasonable royalty;					
4	(iv)	a judgment and order requiring AliveCor to pay Apple the prejudgment and post-				
5	judgment interest to the fullest extent allowed under the law, as well as their costs;					
6	(v)	an order finding that this is an exceptional case and awarding Apple its reasonable				
7	attorneys' fee	s pursuant to 35 U.S.C. § 285; and				
8	(vi)	such other relief as the Court may deem appropriate and just under the circumstances.				
9						
10						

COMPLAINT

Case 5:22-cv-07608 Document 1 Filed 12/02/22 Page 53 of 53

1	DATED: December 2, 2022	Respectfully submitted,	
2		KIRKLAND & ELLIS LLP	
3			
4		/s/ Adam Alper Adam Alper (SBN: 196834)	
5		adam.alper@kirkland.com Akshay S. Deoras (SBN: 30196	2)
6		akshay.deoras@kirkland.com KIRKLAND & ELLIS LLP	,
7		555 California Street San Francisco, CA 94104	
8		Telephone: (415) 439-1400 Facsimile: (415) 439-1500	
9			1001)
10		Michael W. De Vries (SBN: 21) michael.devries@kirkland.com KIRKLAND & ELLIS LLP	1001)
11		555 South Flower Street	
		Los Angeles, CA 90071 Telephone: (213) 680-8400	
12		Facsimile: (213) 680-8500	
13		Leslie M. Schmidt (pending pro leslie.schmidt@kirkland.com	hac vice)
14		KIRKLAND & ELLIS LLP	
15		601 Lexington Avenue New York, NY 10022	
16		Telephone:(212) 446-4800Facsimile:(212) 446-4900	
17		Kat Li (pending pro hac vice)	
18		kat.li@kirkland.com KIRKLAND & ELLIS LLP	
19		401 Congress Avenue Austin, TX 78701	
20		Telephone: (512) 678-9100 Facsimile: (512) 678-9101	
21			
22			
23			
24			
25			
26			
27			
28			
20			
	Complaint	53	CASE NO